{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:40:48Z","timestamp":1792269648828,"version":"4.4.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Since the introduction of the tamper-resistant oral formulation of modified-release oxycodone (OxyContin\u00ae), cases of thrombotic microangiopathy (TMA) have been reported following intravenous injection of the drug. Previous reports have suggested that withdrawal of the offending agent alone may be sufficient to reverse the condition; however, the associated acute kidney injury (AKI) in these cases was only mild to moderate in severity. We report the first case of OxyContin\u00ae-associated TMA presenting with anuric AKI requiring dialysis, followed by complete renal recovery after cessation of intravenous OxyContin\u00ae use. This case demonstrates that withdrawal of the causative agent may be sufficient to achieve resolution of TMA even in severe presentations. Accordingly, supportive management without the need for invasive and costly interventions may be appropriate in selected cases. Awareness of the association between intravenous OxyContin\u00ae use and TMA is essential for timely diagnosis, as identification often depends on direct inquiry regarding drug exposure.<\/jats:p>","DOI":"10.1093\/ckj\/sfag292","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T13:54:38Z","timestamp":1788616478000},"source":"Crossref","is-referenced-by-count":1,"title":["Complete recovery of thrombotic microangiopathy with severe acute kidney injury due to intravenous use of modified release oxycodone"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0788-3758","authenticated-orcid":false,"given":"Moses","family":"Ezeakile","sequence":"first","affiliation":[{"name":"Department of Nephrology, Division of Medicine, Rockhampton, Central Queensland Hospital and Health Services , Queensland ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasnim","family":"Zirapury","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Division of Medicine, Rockhampton, Central Queensland Hospital and Health Services , Queensland ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"2026091201515968200_bib1","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"key":"2026091201515968200_bib2","doi-asserted-by":"publisher","first-page":"330","DOI":"10.5694\/mja14.01125","article-title":"Intravenous OxyContin-associated thrombotic microangiopathy treated successfully without plasma exchange","volume":"202","author":"Tate","year":"2015","journal-title":"Med J Aust"},{"key":"2026091201515968200_bib3","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/ckj\/sfw039","article-title":"Relapsing thrombotic microangiopathy and intravenous sustained-release oxycodone","volume":"9","author":"Nataatmadja","year":"2016","journal-title":"Clin Kidney J"},{"key":"2026091201515968200_bib4","doi-asserted-by":"publisher","first-page":"bcr","DOI":"10.1136\/bcr-2017-220977","article-title":"Thrombotic microangiopathy associated with intravenous injection of extended-release oxycodone","volume":"2017","author":"Robson","year":"2017","journal-title":"BMJ Case Rep"},{"key":"2026091201515968200_bib5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.drugalcdep.2012.12.028","article-title":"Update on tamper-resistant drug formulations","volume":"130","author":"Romach","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"2026091201515968200_bib6","first-page":"1623907","article-title":"Thrombotic microangiopathy secondary to intravenous abuse of Opana\u00ae ER","volume":"2017","author":"Thakur","year":"2017","journal-title":"Case Rep Hematol"},{"key":"2026091201515968200_bib7","first-page":"61","article-title":"Myelotoxicity of high-molecular-weight poly (ethylene oxide)","volume":"67","author":"Karpova","year":"2004","journal-title":"Eksp Klin Farmakol"},{"key":"2026091201515968200_bib8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-1-4614-8432-5_6","article-title":"Properties and applications of polyethylene oxide and ethylcellulose for tamper resistance and controlled drug delivery","volume-title":"Melt Extrusion: Materials, Technology and Drug Product Design","author":"Upadhye","year":"2013"},{"key":"2026091201515968200_bib9","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"key":"2026091201515968200_bib10","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1182\/blood.2023022277","article-title":"Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome","volume":"144","author":"Cataland","year":"2024","journal-title":"Blood"},{"key":"2026091201515968200_bib11","article-title":"Thrombotic microangiopathies (TMAs) with acute kidney injury (AKI) in adults: CM-TMA and ST-HUS","author":"George","year":"2023"},{"key":"2026091201515968200_bib12","doi-asserted-by":"publisher","first-page":"1088031","DOI":"10.3389\/fphar.2022.1088031","article-title":"Drug-induced thrombotic microangiopathy: an updated review of causative drugs, pathophysiology, and management","volume":"13","author":"Mazzierli","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026091201515968200_bib13","article-title":"Drug-induced thrombotic microangiopathy (DITMA)","author":"George","year":"2024"},{"key":"2026091201515968200_bib14","first-page":"616","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood, The J Am Soc Hematol"},{"key":"2026091201515968200_bib15","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2016-08-736579","article-title":"A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER","volume":"129","author":"Hunt","year":"2017","journal-title":"Blood"},{"key":"2026091201515968200_bib16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S2215-0366(18)30003-8","article-title":"The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study","volume":"5","author":"Larance","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"2026091201515968200_bib17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.drugalcdep.2016.09.018","article-title":"Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone","volume":"168","author":"Severtson","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"2026091201515968200_bib18","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s13181-012-0274-7","article-title":"Laboratory testing for prescription opioids","volume":"8","author":"Milone","year":"2012","journal-title":"J Med Toxicol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag292\/70984100\/sfag292.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/9\/sfag292\/70984100\/sfag292.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/9\/sfag292\/70984100\/sfag292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:52:03Z","timestamp":1789192323000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag292\/8787366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag292","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,9,1]]},"article-number":"sfag292"}}